Adam Waldman
Corporate Officer/Principal chez TG THERAPEUTICS, INC.
Profil
Adam Waldman is currently the Chief Commercial Officer at TG Therapeutics, Inc. He previously worked at Celgene Corp.
as the Head of Haematology & Oncology Marketing.
Waldman received an undergraduate degree from Rutgers State University of New Jersey and an MBA from the University of Rochester Simon Business School.
Postes actifs de Adam Waldman
| Sociétés | Poste | Début |
|---|---|---|
| TG THERAPEUTICS, INC. | Corporate Officer/Principal | 04/06/2018 |
Anciens postes connus de Adam Waldman
| Sociétés | Poste | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
Formation de Adam Waldman
| Rutgers State University of New Jersey | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TG THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
